24 October 2002 17:45 [Source: ICIS news]
HOUSTON (CNI)--US pharmaceutical giant Schering-Plough (S-P) reported a 29% decline Thursday in third quarter net income citing a reduction in Claritin trade inventories as US wholesalers prepare for over-the-counter (OTC) sales.
For the quarter ended 30 September, Kenilworth, New Jersey-based S-P posted net income of $429m (Euro437.8m) on a 2% increase in sales to $2.4bn with earnings/share (eps) of 29 cents. Those figures compare with net income of $601m on sales of $2.3bn for the same period last year.
S-P said Claritin - a blockbuster antihistamine - should be available for OTC sales by 28 November.
Meanwhile, S-P said it recorded higher worldwide sales of other pharmaceutical products in the third quarter, including Intron, Remicade, Clarinex, Integrilin and Temodar.
Spending on research and development rose 14% in the quarter to $354m.
For the latest chemical news, data and analysis that directly impacts your business sign up for a free trial to ICIS news - the breaking online news service for the global chemical industry.
Get the facts and analysis behind the headlines from our market leading weekly magazine: sign up to a free trial to ICIS Chemical Business.
|ICIS news FREE TRIAL|
|Get access to breaking chemical news as it happens.|
|ICIS Global Petrochemical Index (IPEX)|
|ICIS Global Petrochemical Index (IPEX). Download the free tabular data and a chart of the historical index|
Asian Chemical Connections